Live RSS
Federal Grant · National Institutes of Health

HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)

Last verified by NonDilute: 2026-06-08. Official notice and agency instructions control.

BiotechHealthcare Tech small-businessstartupuniversity-researcher
The pitch

Up to $100K to rapidly validate overlooked pain protein targets and generate preliminary data that positions you for larger NIH grants.

Award range
Up to $100K
Closes
Jul 16, 2026 · 38d left
Open date
Dec 11, 2024
Difficulty
Medium
Source
Grants.gov
Agency
National Institutes of Health
Last verified
2026-06-08
Fit language
Possible fit only
Apply at grants.gov →

Report stale or inaccurate summary

What this is

This NIH HEAL Initiative grant supports pilot projects generating preliminary data on understudied druggable proteins for pain therapeutics. Awards up to $100,000 fund basic biochemical and biological work to characterize candidate proteins and establish their potential as pain drug targets. The program explicitly excludes clinical trials and targets the opioid crisis by accelerating discovery of novel pain medications. Applicants must focus on proteins designated as understudied within the NIH druggable proteome list.

Who can apply

All nonprofit and for-profit entities are eligible, including small businesses, universities, government agencies, and tribal organizations. Solo researchers must be affiliated with an eligible institution; applications are submitted by institutions, not individuals. No geographic restrictions.

Eligible applicant types

Full description — from the agency

The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to identify new druggable targets for pain within the understudied druggable proteome. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) listed in this NOFO. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.

Topics: pain research · drug discovery · protein targets · understudied druggable proteome · opioid alternatives · HEAL initiative · pilot research · NIH funding

Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.